Treatment of hypertension and prevention of ischemic stroke

Current Cardiology Reports

Volumn 6, Issue 2, 2004, Pages 124-129

  Aronow, Wilbert S ^b   Frishman, William H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; INDAPAMIDE; LISINOPRIL; LOSARTAN; METHYLDOPA; METOPROLOL; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PINDOLOL; PLACEBO; RAMIPRIL; RESERPINE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; HUMAN; HYPERTENSION; INCIDENCE; REVIEW; SYSTOLIC HYPERTENSION; TRANSIENT ISCHEMIC ATTACK; ALGORITHM;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DILTIAZEM; HUMANS; HYPERTENSION; LOSARTAN; PERINDOPRIL;

EID: 2442574225     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0010-2     Document Type: Review

References (32)

1. Garland C, Barrett-Connor E, Suarez L, Criqui MH: Isolated systolic hypertension and mortality after age 60 years. Am J Epidemiol 1983, 118:365-376.
2. Stokes J III, Kannel WB, Wolf PA, et al.: The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 1987, 75(Suppl V):V-65-V-73.
3. Wolf PA: Cerebrovascular disease in the elderly. In Cardiovascular Disease in the Elderly Patient. Edited by Tresch DD, Aronow WS. New York: Marcel Dekker; 1994:125-147.
4. Aronow WS, Ahn C, Gutstein H: Risk factors for new atherothrombotic brain infarction in 664 older men and 1,488 older women. Am J Cardiol 1996, 77:1381-1383.
5. 7 Joint National Committee: The sixth report of the Joint National Committee on the detection, evaluation, and treatment of high blood pressure (JNC VI). Arch Intern Med 1997, 157:2413-2444.
6. Report by the Management Committee: The Australian Therapeutic Trial in Mild Hypertension. Lancet 1980, 1:1261-1267.
7. Medical Research Council Working Party: MRC trial of mild hypertension: principal results. Br Med J 1985, 291:97-104.
8. Medical Research Council Working Party: MRC trial of treatment of hypertension in older adults: principal results. Br Med J 1992, 304:405-412.
9. Amery A, Birkenhager W, Brixko P, et al.: Morbidity and mortality results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985, 1:1349-1354.
10. Coupe J, Warrender TS: Randomised trial of the treatment of hypertension in elderly patients in primary care. Br Med J 1986, 293: 1145-1151.
11. Dahlof B, Lindholm LH, Hansson L, et al.: Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP Hypertension). Lancet 1991, 338:1281-1285.
12. Perry HM Jr., Davis BR, Price TR, et al.: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. The Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000, 284:465-471.
13. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757-764.
14. Wang J-G, Staessen JA, Gong L, et al.: Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 2000, 160:211-220.
15. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
16. Progress Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
17. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal result of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
18. Gueyffier F, Boutitie F, Boissel J-P, et al: Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 1997, 126:761-767.
19. Insua JT, Sacks HS, Lau T-S, et al.: Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994, 121:355-362.
20. Mulrow CD, Cornell JA, Herrera CR, et al.: Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA 1994, 272:1932-1938.
21. Gueyffier F, Bulpitt C, Boissel J-P, et al.: Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999, 353:793-796.
22. Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
23. Hansson L, Linhholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
24. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
25. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
26. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
27. Kjeldsen SE, Dahlof B, Devereux RB: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint Reduction (LIFE) substudy. JAMA 2002, 288:1491-1498.
28. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359: 1004-1010.
29. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000, 283:1967-1975.
30. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
31. Wing LMH, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 248:583-592.
32. Aronow WS: What is the appropriate treatment of hypertension in elders? J Gerontol Med Sci 2002, 57A:M483-M486.